Today, many congenital heart defects can be diagnosed in the unborn child – and even treated in utero. Monique Haak (46), gynaecologist-perinatologist and fetal surgeon at Leids University Medical Center (LUMC) in Leiden, The Netherlands, is an expert in the diagnosis and surgery of fetal heart defects.
Philips TrueVue, GlassVue, aReveal A.I. and TouchVue improve workflow and diagnostic confidence, enhancing the connection between clinicians and their patients.
The Acuson NX3* and Acuson NX3 Elite*, two new ultrasound systems from Siemens Healthcare, are on show at this year’s Medica Trade Fair. ‘Both mid-range systems offer a simple, intuitive interface combined with innovative imaging solutions for examinations primarily in general medicine, obstetrics/gynaecology, paediatrics and neurology,’ the manufacturer reports.
The new Philips Avalon CL’s cable-less design enables mothers to move more freely during labour and uses Smart Pulse technology to automatically detect the coincidence between maternal pulse and foetal heart rate, even for twins and triplets.
The survival of premature newborns in England is 30% higher in specialist units treating large numbers of neonates, reveals an analysis of national data published in the online journal BMJ Open.
HRH the Duke of Kent, President of King Edward VII’s Hospital, today officially re-opened the expanded outpatients unit at Emmanuel Kaye House in London. The Hospital’s newly refurbished unit has doubled in size and will now offer eleven consulting rooms to accompany the growing number of patients
New Assay Is First to Standardize to World Health Organization’s 5th International Standard for Chorionic Gonadotropin
Down’s syndrome (also referred to as trisomy 21) is a genetic disorder caused by the presence of all or part of an extra copy of chromosome 21 in a person’s DNA.
Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.
Modern imaging techniques greatly enhance the treatment selection
Hedvig Hricak, Chair of the Radiology Department at the Memorial Sloan-Kettering Cancer Center, New York, USA, describes emerging applications and potential trends in gynaecological cancer treatment described at the 15th International Symposium Crossing Barriers
GE Healthcare yesterday announced the availability of the Giraffe® Stand-Alone Infant Resuscitation (STAR) System, which integrates critical capabilities to enhance effective resuscitation of newborns.
Accuvix A30 produces impressive results in the prenatal diagnostics arena and Samsung could become a serious contender in the ultrasound champions’ league.
‘The egg timer test’ is widely used to help determine how long a woman can expect to remain fertile. Lately it has shown even greater potential for clinical use as a biomarker for ovarian viability.
Suspicion of venous thromboembolism (VTE) in a pregnant patient will quickly bring a radiologist to a choice, where the next step holds potentially significant consequences for both the mother and unborn child.
In 2012, Chicago’s Children’s Memorial Hospital will be in transition, with a change of name as well as location, when its top class technology, physicians, scientists, staff and patients transfer to a new state-of-the-art complex three miles away.
‘As we become more successful in the early detection and treatment of breast cancer, we tend to trivialise it. Yet one in 9 women still get breast cancer. Half of them become depressed, their partners don’t know how to react and their families are in disarray. We need to stop trivialising breast cancer. It kills women.’ So says Dr Fabienne Liebens, Head of the Saint-Pierre Hospital’s…
Catastrophes draw people closer, as demonstrated by the development of the new high-end ultrasound scanner Aplio 500 from Toshiba. The clinical evaluation period took place during the tsunami and the nuclear catastrophe in Fukusima. Professor Thomas Fischer at the Radiological Institute, Charité Clinic in Berlin, was impressed by the enormous commitment shown by the Japanese firm’s engineers…
Prenatal ultrasound images are the first images we see of new humans. But the prenatal ultrasound first carried out by Professor Ian Donald in the late 50s has little to do with today’s potential with 3-D and 4-D imaging with Doppler and colour Doppler. The three tightly linked disciplines gynaecology, prenatal medicine and obstetrics would now be inconceivable without ultrasound
The birth, in France, of its first baby to be conceived by artificial insemination on top of the selection of an embryo based on its blood, has sent new flames into the hot parliamentary debate over the reform of bioethics law.
As one of the first in Europe, the FUS Centre at the Klinikum Dachau in Germany introduced MRgFUS in 2008 as a gentle alternative for the treatment of fibroids. The success that has since been achieved in this encouraged Dr Matthias Matzko, head of radiology and of the FUS Centre, to take on a leading role with the introduction to the market of the second product generation, the ExAblate One.…
Philips Electronics and Atom Medical Corporation, a major manufacturer of neonatal medical equipment, announced today that they are expanding their relationship to serve customers with a more complete portfolio of perinatal care solutions.
Ultrasound is the undisputed choice for foetal imaging. However, the lack of amniotic fluid, an unfavourable foetal position or maternal obesity could daunt even the best radiographer. In such circumstances prenatal magnetic resonance imaging (MRI) – a non-invasive and non-irradiating procedure – is a helpful diagnostic tool.
Current cervical cancer screening is time consuming and expensive, but now new breakthrough technology developed by European researchers should allow large-range screening by non-medical personnel with almost immediate results and at a much lower cost.
Data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) USA registration trial, involving more than 47,000 women, demonstrate that two human papilloma virus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.
